Why the anti-Covid pill is elle si peu used in France?

Conseillé aux personnes à risque de serious forms, le Paxlovir was only prescribed to 20,000 patients, selon l’Assurance maladie. IPA/IPA/Sipa USA via Reuters Connect

DÉCRYPTAGE – Le Paxlovid nevertheless benefits from sufficient stocks and effective medical efficacy.

Six months after its authorization, Paxlovid remains very little used. L’efficacy du seul antiviral autorisé en France est pourtant prouvée: it reduces by 87.8% the risk of progression towards serious forms of Covid (spitalisation or death) when taken within five days after l’apparition des premiers symptoms. Conseillé aux personnes at risk of serious forms – porteuses de comorbidités ou immunodeprimées, et aux plus de 60 ans – it was only prescribed to 20,000 patients, selon l’Assurance-maladie. Un chiffre dérisoire quand on sait que pour la seule journée du 22 juillet, 971 nouveaux cases were censused chez les plus de 60 ans, selon Santé publique France. This would not be a stock problem, the one being sufficient “to cover current needs and to come”, assures the Ministry of Health, which nevertheless refuses to give its exact level.

“What name is insufficient compared to the United States by example, where at the Test & Treat strategy (diagnostic et soigner…

This article is reserved for subscribers. You have 82% left to discover.

Repousser les limites de la science, c’est aussi ça la liberté.

I continue à lire your article for €0.99 le premier mois

Already subscribed? Connect-vous

.

Leave a Comment